Show simple item record

dc.contributor.authorZhu, Huaiyangen_US
dc.contributor.authorLeiss, Lina Wiken_US
dc.contributor.authorYang, Ningen_US
dc.contributor.authorRygh, Cecilie Brekkeen_US
dc.contributor.authorMitra, Siddharta S.en_US
dc.contributor.authorCheshier, Samuel H.en_US
dc.contributor.authorWeissman, Irving L.en_US
dc.contributor.authorHuang, Binen_US
dc.contributor.authorMiletic, Hrvojeen_US
dc.contributor.authorBjerkvig, Rolfen_US
dc.contributor.authorEnger, Per Øyvinden_US
dc.contributor.authorLi, Xingangen_US
dc.contributor.authorWang, Jianen_US
dc.PublishedZhu H, Leiss LW, Yang N, Rygh CB, Mitra SS, Cheshier, Weissman IL, Huang B, Miletic H, Bjerkvig R, Enger PØ, Li X, Wang J. Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy. OncoTarget. 2017;8(7):12145-12157eng
dc.description.abstractSurgical resection is a standard component of treatment in the clinical management of patients with glioblastoma multiforme (GBM). However, experimental therapies are rarely investigated in the context of tumor debulking in preclinical models. Here, a surgical debulking GBM xenograft model was developed in nude rats, and was used in combination with CD47 blocking immunotherapy, a novel treatment strategy that triggers phagocytosis of tumor cells by macrophages in diverse cancer types including GBM. Orthotopic patient–derived xenograft tumors expressing CD47 were resected at 4 weeks after implantation and immediately thereafter treated with anti-CD47 or control antibodies injected into the cavity. Debulking prolonged survival (median survival, 68.5 vs 42.5 days, debulking and non-debulking survival times, respectively; n = 6 animals/group; P = 0.0005). Survival was further improved in animals that underwent combination treatment with anti-CD47 mAbs (median survival, 81.5 days vs 69 days, debulking + anti-CD47 vs debulking + control IgG, respectively; P = 0.0007). Immunohistochemistical staining of tumor sections revealed an increase in recruitment of cells positive for CD68, a marker for macrophages/immune cell types, to the surgical site (50% vs 10%, debulking vs non-debulking, respectively). Finally, analysis of tumor protein lysates on antibody microarrays demonstrated an increase in pro-inflammatory cytokines, such as CXCL10, and a decrease in angiogenic proteins in debulking + anti-CD47 vs non-debulking + IgG tumors. The results indicated that surgical resection combined with anti-CD47 blocking immunotherapy promoted an inflammatory response and prolonged survival in animals, and is therefore an attractive strategy for clinical translation.en_US
dc.publisherImpact Journalseng
dc.rightsAttribution CC BYeng
dc.subjectsignal regulatory protein-αeng
dc.titleSurgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapyen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2017 The Author(s)

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY